AbbVie Inc.’s blockbuster cancer treatment Imbruvica in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.
An Opdivo-Yervoy combo yielded a significantly longer treatment-free survival period for patients with previously untreated advanced or metastatic renal cell carcinoma than standard of care sunitinib.
Imbruvica Plus Gazyva Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia Patients Met Primary Endpoint
Biopharma, Bruton's Tyrosine Kinase (BTK) Inhibitors, Chronic Lymphocytic Leukemia (CLL), Clinical Studies, Progression-Free Survival (PFS), Small Lymphocytic Lymphoma (SLL)AbbVie, a research-based global biopharmaceutical company, announced that the Phase 3 iLLUMINATE (PCYC-1130) trial met its primary endpoint of improvement in progression-free survival.
A combination of experimental drugs from Array BioPharma Inc. kept patients with advanced melanoma associated with a common gene mutation alive for nearly three years and twice as long as a rival Roche Holding AG medicine, according to data from a late-stage study.
Genentech announced results from the positive Phase III IMmotion151 study of Tecentriq (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for advanced or metastatic renal cell carcinoma.
Shares of Bristol-Myers Squibb climbed after announcing its anticipated Phase III CheckMate-227 study met its endpoints of progression-free survival as a first-line lung cancer treatment.
The DUO study showed statistically significant PFS improvement for duvelisib versus standard of care treatment ofatumumab.
